Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. The three Alcon businesses - Surgical, Pharmaceutical and Vision Care - offer the widest spectrum of eye care products in the world. Alcon is the second largest division of the Novartis Group with sales of USD 10.2 billion in 2012. Headquartered in Fort Worth, Texas, USA, Alcon has more than 24,000 employees worldwide, operations in 75 countries and products available in 180 markets. For more information, visit http://www.alcon.com.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations , and , accordingly , entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement , whether as a result of new information , future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933 , as amended , or in compliance with an exemption therefrom , and in accordance with any applicable U.S. state securities laws.For further information please contact: Thrombogenics Wouter Piepers, Global Head of Corporate Communications +32-16-75-13-10 / +32 478 33 56 32 Wouter.email@example.com Dr. Patrik De Haes, CEO +32-16-75-13-10 Patrik.firstname.lastname@example.org Chris Buyse, CFO +32-16-75-13-10 Chris.email@example.com Citigate Dewe Rogerson David Dible/ Sita Shah Tel: +44-20-7638-9571 firstname.lastname@example.org The Trout Group (US investor relations) Todd James/ Simon Harnest Tel: +1-646-378-2926 email@example.com SOURCE ThromboGenics